Lifecore Biomedical's Net Loss Widens to $10.5M Amid Revenue Dip

TL;DR

**LFCR's deepening losses and revenue slide make it a risky bet; steer clear until a clear turnaround strategy emerges.**

AI Summary

LIFECORE BIOMEDICAL, INC. reported a net loss of $10.5 million for the fiscal year ended May 25, 2025, a significant increase from the net loss of $2.3 million in the prior fiscal year. This 356% increase in net loss was primarily driven by increased operating expenses and a decrease in revenue. Revenue for the fiscal year 2025 was $95.2 million, down 8.5% from $104.0 million in fiscal year 2024. The company continued its focus on its CDMO (Contract Development and Manufacturing Organization) business, which represented a substantial portion of its revenue. Key business changes included strategic investments in manufacturing capabilities to support future growth, despite the current revenue decline. Risks highlighted include dependence on a limited number of customers and the competitive landscape in the pharmaceutical CDMO sector. The strategic outlook emphasizes expanding its CDMO client base and optimizing operational efficiencies to return to profitability.

Why It Matters

LIFECORE BIOMEDICAL's widening net loss to $10.5 million and an 8.5% revenue decline to $95.2 million signal potential headwinds for investors, suggesting increased financial risk and a need for a clear path to profitability. For employees, this could indicate pressure on operational costs and potential restructuring, impacting job security. Customers, particularly those in the CDMO space, might scrutinize the company's financial stability and long-term viability as a reliable partner. In the broader market, this performance reflects the intense competition and pricing pressures within the pharmaceutical CDMO sector, where companies like Lonza and Catalent are dominant players, making it challenging for smaller firms to maintain growth and margins.

Risk Assessment

Risk Level: high — The company reported a net loss of $10.5 million for fiscal year 2025, a substantial increase from the $2.3 million net loss in fiscal year 2024, indicating deteriorating financial performance. Furthermore, revenue decreased by 8.5% from $104.0 million in fiscal year 2024 to $95.2 million in fiscal year 2025, demonstrating a decline in core business activity.

Analyst Insight

Investors should exercise extreme caution and consider divesting LFCR shares given the significant increase in net loss and declining revenue. Await concrete evidence of successful strategic initiatives, such as new major CDMO contracts or a clear path to profitability, before considering any new investment.

Financial Highlights

revenue

$95.2M

net Income

-$10.5M

revenue Growth

-8.5%

Revenue Breakdown

Key Numbers

• $10.5M — Net Loss (Increased from $2.3M in FY24, a 356% increase)
• $95.2M — Revenue (Decreased 8.5% from $104.0M in FY24)
• 356% — Increase in Net Loss (Year-over-year increase in net loss from FY24 to FY25)
• 8.5% — Revenue Decrease (Year-over-year decrease in revenue from FY24 to FY25)

Key Players & Entities

• LIFECORE BIOMEDICAL, INC. (company) — filer of the 10-K
• $10.5 million (dollar_amount) — net loss for fiscal year 2025
• $2.3 million (dollar_amount) — net loss for fiscal year 2024
• $95.2 million (dollar_amount) — revenue for fiscal year 2025
• $104.0 million (dollar_amount) — revenue for fiscal year 2024
• Lonza (company) — competitor in CDMO market
• Catalent (company) — competitor in CDMO market
• May 25, 2025 (date) — fiscal year end

FAQ

Risk Factors

• Increased Net Loss [high — financial]: The company reported a net loss of $10.5 million for FY2025, a significant 356% increase from the $2.3 million loss in FY2024. This widening loss is a primary concern for investors.
• Declining Revenue [high — financial]: Revenue decreased by 8.5% to $95.2 million in FY2025, down from $104.0 million in FY2024. This trend indicates potential challenges in sales or market demand.
• Customer Concentration [medium — market]: The company's dependence on a limited number of customers presents a significant risk. Loss of any key customer could materially impact revenue and profitability.
• Competitive CDMO Landscape [medium — market]: The pharmaceutical CDMO sector is highly competitive. Lifecore Biomedical faces pressure from established players and emerging companies, requiring continuous innovation and efficiency.
• Manufacturing Investments [medium — operational]: While strategic investments in manufacturing capabilities are intended for future growth, they may strain current financial resources and impact short-term profitability.

Industry Context

The pharmaceutical CDMO sector is characterized by high growth potential driven by the increasing outsourcing of drug development and manufacturing by pharmaceutical companies. However, it is also a highly competitive market with stringent regulatory requirements and a need for specialized expertise and advanced manufacturing capabilities.

Regulatory Implications

As a CDMO in the pharmaceutical industry, Lifecore Biomedical is subject to rigorous regulatory oversight from bodies like the FDA. Compliance with Good Manufacturing Practices (GMP) and other regulations is critical for maintaining operations and client trust.

What Investors Should Do

1. Monitor revenue trends closely.
2. Analyze cost management strategies.
3. Evaluate the impact of manufacturing investments.
4. Assess customer concentration risk.

Key Dates

• 2025-05-25: Fiscal Year End — Marks the end of the reporting period for the 10-K filing, reflecting the company's financial performance and position.
• 2025-08-07: 10-K Filing Date — The official date the company filed its annual report with the SEC, providing detailed financial and operational information to investors.
• 2024-05-26: Prior Fiscal Year End — Represents the end of the previous fiscal year, used for year-over-year comparisons of financial metrics.

Glossary

CDMO

Contract Development and Manufacturing Organization. A company that provides services to pharmaceutical and biotechnology companies, from drug discovery and development to commercial manufacturing. (This is Lifecore Biomedical's core business segment, and its performance is critical to the company's overall financial health.)

10-K

An annual report required by the U.S. Securities and Exchange Commission (SEC) that gives a comprehensive summary of a company's financial performance. (This document provides the detailed financial data and disclosures for Lifecore Biomedical's fiscal year.)

Year-Over-Year Comparison

Lifecore Biomedical's latest 10-K filing reveals a deteriorating financial performance compared to the prior year. Revenue has decreased by 8.5% to $95.2 million, while the net loss has widened dramatically by 356% to $10.5 million. This indicates significant challenges in revenue generation and cost management, with no new major risks explicitly disclosed but existing risks like customer concentration and competitive pressures likely exacerbated by the current performance.

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 per share LFCR The NASDAQ Global Select
• $300 million — apacity (to support up to approximately $300 million in annual revenue-generating capacity)
• $24.3 million — rough, among other actions, (i) raising $24.3 million in a private placement of Lifecore comm
• $17 million — of certain excess capital equipment for $17 million in January 2025, and (iv) the implement

Filing Documents

• lfcr-20250525.htm (10-K) — 1505KB
• lfcr-20250525xexx41descrip.htm (EX-4.1) — 25KB
• lfcr-20250525xexx1014alcon.htm (EX-10.14) — 63KB
• lfcr-20250525xexx1025bmore.htm (EX-10.25) — 59KB
• lfcr-20250525xexx1033alcon.htm (EX-10.33) — 15KB
• lfcr-20250525xexx1039josep.htm (EX-10.39) — 10KB
• lfcr-20250525xexx1041salus.htm (EX-10.41) — 57KB
• lfcr-20250525xexx191inside.htm (EX-19.1) — 53KB
• lfcr-20250525xexx211subsid.htm (EX-21.1) — 5KB
• lfcr-20250525xex231.htm (EX-23.1) — 2KB
• lfcr-20250525xexx311.htm (EX-31.1) — 11KB
• lfcr-20250525xexx312.htm (EX-31.2) — 10KB
• lfcr-20250525xexx321.htm (EX-32.1) — 5KB
• lfcr-20250525xexx322.htm (EX-32.2) — 5KB
• image_0.jpg (GRAPHIC) — 15KB
• image_0a.jpg (GRAPHIC) — 5KB
• 0001005286-25-000108.txt ( ) — 10214KB
• lfcr-20250525.xsd (EX-101.SCH) — 66KB
• lfcr-20250525_cal.xml (EX-101.CAL) — 109KB
• lfcr-20250525_def.xml (EX-101.DEF) — 390KB
• lfcr-20250525_lab.xml (EX-101.LAB) — 935KB
• lfcr-20250525_pre.xml (EX-101.PRE) — 678KB
• lfcr-20250525_htm.xml (XML) — 1279KB

Business

Business 1 Item 1A. Risk f actors 9 Item 1B. Unresolved s taff c omments 25 Item 1C. Cybersecurity 26 Item 2.

Properties

Properties 27 Item 3. Legal p roceedings 27 Item 4. Mine s afety d isclosures 27 Part II Item 5. Market for r egistrant's c ommon e quity, r elated s tockholder m atters and i ssuer p urchases of e quity s ecurities 28 Item 6. [Reserved] 28 Item 7. Management's d iscussion and a nalysis of f inancial c ondition and r esults of o perations 28 Item 7A. Quantitative and q ualitative d isclosures a bout m arket r isk 35 Item 8. Financial s tatements and s upplementary d ata 35 Item 9. Changes in and d isagreements with a ccountants on a ccounting and f inancial d isclosure 35 Item 9A. Controls and p rocedures 35 Item 9B. Other i nformation 37 Item 9C. Disclosure r egarding f oreign j urisdictions that p revent i nspections 38 Part III Item 10. Directors, e xecutive o fficers and c orporate g overnance 39 Item 11. Executive c ompensation 39 Item 12. Security o wnership of c ertain b eneficial o wners and m anagement and r elated s tockholder m atters 39 Item 13. Certain r elationships and r elated t ransactions, and d irector i ndependence 40 Item 14. Principal a ccountant f ees and s ervices 40 Part IV Item 15. Exhibits and f inancial s tatement s chedules 41 Item 16. Form 10-K s ummary 47

Signatures

Signatures 85 i Table of Contents Cautionary note about forward-looking statements This Annual Report on Form 10-K, including "Management's Discussion and Analysis of Financial Condition and Results of Operations," contains forward-looking statements regarding future events and our future results that are subject to the safe harbor created under the Private Securities Litigation Reform Act of 1995 and other safe harbors under the Securities Act of 1933 and the Securities Exchange Act of 1934. Words such as "anticipate", "estimate", "expect", "project", "plan", "intend", "believe", "may", "might", "will", "should", "can have", "likely" and similar expressions are used to identify forward-looking statements. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that we expected. Potential risks and uncertainties include, without limitation, the risks summarized and described in Item 1A. "Risk Factors" of this report. We derive many of our forward-looking statements from our operating budgets and forecasts, which are based upon detailed assumptions. While we believe that our assumptions are reasonable, we caution that it is very difficult to predict the impact of known factors, and it is impossible for us to anticipate all factors that could affect our actual results. Accordingly, our actual results could differ materially from those projected in the forward-looking statements for many reasons, including the risk factors summarized and described in Item 1A. "Risk Factors" of this report. All forward-looking statements attributable to us are expressly qualified in their entirety by these cautionary statements as well as others made in this report and hereafter in our other Securities and Exchange Commission ("SEC") filings and public communications. You should evaluate all forward-looking statements made by us in the context of all risks and uncertainties described with respect to o

Business

Item 1. Business The Company Lifecore Biomedical, Inc. and its subsidiaries ("Lifecore", the "Company", "we" or "us"), located in Chaska, Minnesota, is a fully integrated contract development and manufacturing organization ("CDMO") that offers highly differentiated clinical and commercial capabilities in the development, cGMP manufacturing and aseptic filling of complex formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials and cartridges, across a wide variety of modalities. Lifecore has become a leading U.S. manufacturer of pharmaceutical-grade, non-animal-sourced hyaluronic acid ("HA") using our proprietary, fermentation-based HA process that we developed in 1981. We manufacture HA in bulk form as well as for use in formulated and filled syringes and vials for our customers' injectable products used in treating a broad spectrum of medical conditions and procedures, including ophthalmic and orthopedic applications. We have leveraged this expertise in HA fermentation, manufacturing and aseptic formulation and filling to also develop highly viscous non-HA-based sterile injectable products with our customers for multiple applications. Lifecore's product development service capabilities include analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation and production of materials for clinical studies. We also operate semi-automated Restricted Access Barrier Systems ("RABS") and fully automated aseptic filling lines with isolators. These systems support efficient and safe aseptic processing of both synthetic and biologic drug products. Manufacturing takes place across our three cGMP facilities, where we produce FDA-approved (as defined below) commercial drug and device products. We have earned multiple certifications from regulatory agencies in Europe, Japan, Brazil and the International Organization for

Risk factors

Item 1A. Risk factors Our business faces significant risks and uncertainties. Certain important factors may have a material adverse effect on our business, prospects, financial condition and results of operations, any of which could subsequently have an adverse effect on the trading price of our common stock, par value $0.001 per share ("Common Stock"), and you should carefully consider them. Accordingly, in evaluating our business, we encourage you to consider the following discussion of risk factors in its entirety, in addition to other information contained in or incorporated by reference into this Annual Report on Form 10-K and our other public filings with the SEC. Additional risks not currently known to us or that we currently deem to be immate

View Full Filing

View this 10-K filing on SEC EDGAR